Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

BACKGROUND: We assessed the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine. METHODS: A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety and immunogenicity of the COVID-19 vaccine Corbevax and select to an optimum formulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuluva, Subhash, Paradkar, Vikram, Gunneri, Subba Reddy, Yerroju, Vijay, Mogulla, Rammohan, Turaga, Kishore, Kyasani, Mahesh, Manoharan, Senthil Kumar, Medigeshi, Guruprasad, Singh, Janmejay, Shaman, Heena, Singh, Chandramani, Rao A, Venkateshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372721/
https://www.ncbi.nlm.nih.gov/pubmed/35970020
http://dx.doi.org/10.1016/j.ebiom.2022.104217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372721/
https://www.ncbi.nlm.nih.gov/pubmed/35970020
http://dx.doi.org/10.1016/j.ebiom.2022.104217

Ejemplares similares